Hear from the leading figures in the digital biomarkers and Alzheimer’s disease field and benefit from in-depth discussion of how digital biomarkers can be utilised in neuroscience and clinical development
The interactive workshop provides an in-depth look at digital biomarkers for Alzheimer’s disease, bringing together stakeholders from leading academic, charitable and biotech organisations specialising in neurodegenerative disorders.
It includes 3-hours of action-packed live presentations and discussions from industry experts.
Full details for the Virtual Workshop are available in the Conference Brochure.
If you are interested in attending this virtual event, please register your details with us and we will contact you once registration opens.
Our LinkedIn group aims to foster discussion and collaboration between experts working in biomarker research and clinical development.
Effective treatments for Alzheimer’s disease (AD) have remained largely elusive, likely in part, because of the etiological heterogeneity that suggests multiple treatment pathways. The vast majority of AD clinical studies remain centered on using peer-defined methods that lead to collecting the same data in the same way, analyzing the data in the same way and not surprisingly, finding essentially the same results. Technological advances provide an opportunity to break out of this repetitive cycle of failure and do so by reducing costs, compressing timelines and accelerating innovation and discovery. While thematically centered on AD, this panel illuminates key areas in the clinical trial pipeline that could be transformed and is applicable for numerous chronic disease states.
The Workshop brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.
Boston University School of Medicine
Alzheimer’s Research UK
Networking & knowledge-sharing is at the heart of what we do. Alongside the focussed programme, attendees can make the most of participation through interacting with other attendees.